Baricitinib, a JAK1/2 inhibitor, improved skin symptoms in the Phase III SLE-BRAVE I trial; however, these findings were not replicated in SLE-BRAVE II [146]. This evidence concerns the gene JAK1 and systemic lupus erythematosus.